Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2442 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
(1-Nitroethene-1,2-diyl)dibenzene
CAS:(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.Fórmula:C14H11NO2Cor e Forma:SolidPeso molecular:225.24CM-414
CAS:CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.Fórmula:C23H29N5O4Pureza:98%Cor e Forma:SolidPeso molecular:439.51RL5a
CAS:RL5a (compound C23) is a novel inhibitor of SETD8.Fórmula:C17H19N3OCor e Forma:SolidPeso molecular:281.35PARP14 inhibitor 1
CAS:<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Fórmula:C23H27FN4O3Cor e Forma:SolidPeso molecular:426.484XP5
XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).Fórmula:C19H25N3O5SCor e Forma:SolidPeso molecular:407.48QCA570
CAS:QCA570 is an effective BET degrader based on PROTAC (IC50: 10 nM for BRD4 BD1 Protein).Fórmula:C39H33N7O4SPureza:98%Cor e Forma:SolidPeso molecular:695.79PKCiota-IN-1
CAS:PKCiota-IN-1: Strong PKC-ι inhibitor (IC50=2.7 nM); also blocks PKC-α/ε (IC50s=45/450 nM).Fórmula:C25H22FN5OCor e Forma:SolidPeso molecular:427.47Enzomenib
CAS:Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.Fórmula:C33H43FN6O3Cor e Forma:SolidPeso molecular:590.73WDR5-IN-5
CAS:WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.Fórmula:C29H29F3N6OCor e Forma:SolidPeso molecular:534.58JAK1/TYK2-IN-4
CAS:JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Fórmula:C17H23N7OCor e Forma:SolidPeso molecular:341.41Menin-MLL inhibitor 26
CAS:Menin-MLL inhibitor 26: Active reference, inhibits cell growth, used in leukemia research.Fórmula:C27H29F3N6O3SCor e Forma:SolidPeso molecular:574.62JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFórmula:C17H20N6OPureza:98.81%Cor e Forma:SolidPeso molecular:324.38GSK8814
CAS:GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan).Fórmula:C28H35F2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:527.61(2S,3R)-LP99
CAS:(2S,3R)-LP99 is a less active enantiomer of LP99.Fórmula:C26H30ClN3O4SPureza:98%Cor e Forma:SolidPeso molecular:516.05JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Cor e Forma:SolidTyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Fórmula:C21H25F2N7OCor e Forma:SolidPeso molecular:429.47MI-1481
CAS:MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.Fórmula:C29H30F3N7O2SPureza:98%Cor e Forma:SolidPeso molecular:597.65RU-0415529
CAS:RU-0415529 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (NSP14), with an IC50 of 356 nM. It inhibits viral RNA methylation and replication by stabilizing the cap-binding pocket through SAH binding. Additionally, RU-0415529 exhibits anti-infective activity in mouse models.Fórmula:C21H29N3O4SCor e Forma:SolidPeso molecular:419.538PARP1-IN-5
PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.Fórmula:C25H24N2O5SCor e Forma:SolidPeso molecular:464.53MMSET-IN-1
CAS:MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .Fórmula:C18H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:423.47Equisetin
CAS:Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.Fórmula:C22H31NO4Pureza:98%Cor e Forma:SolidPeso molecular:373.49PARP7-IN-23
CAS:<p>PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells, indicating its potential for cancer research.</p>Fórmula:C27H22F7N5O3Cor e Forma:SolidPeso molecular:597.484Aurora A inhibitor 1
CAS:Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)Fórmula:C25H28ClF2N5O2Cor e Forma:SolidPeso molecular:503.97MS8511
CAS:<p>MS8511: Selective, irreversible G9a/GLP inhibitor. IC50: 100 nM (G9a), 140 nM (GLP). Lowers H3K9me2, anti-proliferative. Useful in cancer/AD/PWS research.</p>Fórmula:C28H41N5O3Cor e Forma:SolidPeso molecular:495.66SGC6870N
CAS:<p>SGC6870N is inactive against PRMT6 and can be used as a negative control. It is the inactive enantiomer of SGC6870.</p>Fórmula:C23H21BrN2O2SPeso molecular:469.39CFT8634
CAS:CFT8634 degrades BRD9, for synovial sarcoma and SMARCB1 tumor research, from patent WO2021178920A1.Fórmula:C37H45F3N6O5Cor e Forma:SolidPeso molecular:710.79MTL-CEBPA
MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.Cor e Forma:SolidSMARCA2/4-ligand-5
CAS:<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Fórmula:C20H13ClN4O3Cor e Forma:SolidPeso molecular:392.795CARM1-IN-3 dihydrochloride
CARM1-IN-3 dihydrochloride (17b) is a potent CARM1 inhibitor (IC50: 0.07 μM) with selectivity over CARM3 (IC50 >25 μM).Fórmula:C24H34Cl2N4O2Cor e Forma:SolidPeso molecular:481.46PARP1-IN-29
CAS:PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.Fórmula:C18H16FN3O2Cor e Forma:SolidPeso molecular:325.34LSD1-IN-35
CAS:LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.Fórmula:C25H26N4O2SCor e Forma:SolidPeso molecular:446.57Menin-MLL inhibitor 4
CAS:Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .Fórmula:C32H38FN7O3Pureza:98%Cor e Forma:SolidPeso molecular:587.69Aurora inhibitor 1
CAS:Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).Fórmula:C23H25N9SPureza:98%Cor e Forma:SolidPeso molecular:459.57HuR degrader 2
CAS:HuRdegrader 2 (Compound 3) is a molecular glue that targets and degrades the RNA-binding protein Hu antigen R (HuR), achieving 30% degradation at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 of ≤200 nM. HuRdegrader 2 also shows high affinity for cereblon with an HTRF ratio < 0.02.Fórmula:C20H15N3O3Peso molecular:345.35GNE-886
CAS:GNE-886 has a wide range of applications in life science related research.Fórmula:C28H30N6O3Pureza:98%Cor e Forma:SolidPeso molecular:498.59Octyl-α-hydroxyglutarate
CAS:<p>Octyl-α-hydroxyglutarate (octyl-2-HG) enhances histone methylation and boosts the viability of LMP1-negative nasopharyngeal carcinoma (NPC) cells.</p>Fórmula:C13H24O5Peso molecular:260.33JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFórmula:C22H17FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:448.47LSD1-IN-16
LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43KAT6A-IN-2
CAS:KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.Fórmula:C23H29N5O5SCor e Forma:SolidPeso molecular:487.57KAT6A-IN-1
CAS:KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.Fórmula:C23H27N5O5SCor e Forma:SolidPeso molecular:485.56HLCL-61
CAS:HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).Fórmula:C23H24N2OCor e Forma:SolidPeso molecular:344.45GSK789
CAS:GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.Fórmula:C26H33N5O3Cor e Forma:SolidPeso molecular:463.57PFI-6-COOH
CAS:PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.Fórmula:C23H21N3O6Cor e Forma:SolidPeso molecular:435.43YTH-IN-1
CAS:YTH-IN-1 is an inhibitor of the five YTH structural domains in the human.The YTH family of proteins is an N 6-methyladenosine (m6A) reader in gene expression.Fórmula:C18H24N6O3Pureza:98.46% - 99.94%Cor e Forma:SolidPeso molecular:372.42EZM0414
CAS:EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay.Fórmula:C22H29FN4O2Pureza:99.58%Cor e Forma:SolidPeso molecular:400.49Pocenbrodib
CAS:<p>Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.</p>Fórmula:C28H32FN3O6Pureza:98.48% - 99.54%Cor e Forma:SolidPeso molecular:525.57BAY-3827
CAS:BAY-3827 is an AMPK inhibitor with antiproliferative activity and antitumor activity. BAY-3827 inhibits the phosphorylation of acetyl CoA carboxylase 1.Fórmula:C27H25FN6OPureza:99.90%Cor e Forma:SolidPeso molecular:468.53Ref: TM-T73350
1mg56,00€5mg119,00€10mg187,00€25mg354,00€50mg590,00€100mg835,00€500mg1.663,00€1mL*10mM (DMSO)124,00€GSK3368715 dihydrochloride
CAS:GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is a PRMTs inhibitor , with anticancer activity, for the study of advanced solid tumors.Fórmula:C20H40Cl2N4O2Pureza:99.66% - 99.66%Cor e Forma:SolidPeso molecular:439.46INCB054329
CAS:INCB054329 is a BET inhibitor targeting BRD2/3/4 and BRDT with IC50s ranging from 1-119 nM.Fórmula:C19H16N4O3Pureza:99.52%Cor e Forma:SolidPeso molecular:348.36LLY-283
CAS:LLY-283, PRMT5 inhibitor, IC50 22 nM, Kd 6 nM, oral, selective, with antitumor effects.Fórmula:C17H18N4O4Pureza:99.49%Cor e Forma:SolidPeso molecular:342.35
